Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

LGC Group GB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Innovation Day

Participation Not Confirmed

Update your events

OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA

Contact the Supplier

Lead Product(s): OLX301D

Therapeutic Area: Ophthalmology Product Name: OLX301D

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: OliX Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 16, 2020

Details:

Under the terms of the agreement, LGC will produce the active pharmaceutical ingredients for the preclinical and clinical study of OLX301D program, for the treatment of sub-retinal fibrosis and wet macular degeneration.